Product Description
a novel ligand of the nociceptin/orphanin FQ (N/OFQ) peptide receptor, NOP. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/12237257/)
Mechanisms of Action: NOP Agonist
Novel Mechanism: Yes
Modality: Peptide/Protein
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Zealand Pharma
Company Location: COPENHAGEN G7 00000
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Heart Failure, Acute|Heart Failure, Chronic
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2004-004801-11 |
2004-004801-11 | P2 |
Completed |
Heart Failure, Acute|Heart Failure, Chronic |
2025-01-30 |
2025-05-06 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |